India’s diagnostics giants are racing past routine blood tests into genomics, AI pathology and liquid biopsy, building high-tech moats that discounters cannot copy and the market is already pricing in.
TCS’s chairman N Chandrasekaran told the 31st AGM that AI is the biggest opportunity in TCS’s history, no downsizing is planned, and all revenue will be AI-linked by 2030. The annual report says otherwise on every count.
Newsletter
Search
